Skip to main content

ADVERTISEMENT

prostate cancer

From the Field
03/16/2022
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues...
03/16/2022
Journal of Clinical Pathways
FDA Approves Relugolix for Advanced Prostate Cancer
FDA Alerts
12/18/2020
Journal of Clinical Pathways
News
12/01/2020
Journal of Clinical Pathways
Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer Treatment: An Interview With  Joseph J. Busch, Jr., MD
Interview
04/18/2020
Dr Busch is the owner of the Busch Center, an imaging center in Alpharetta, Georgia that is dedicated to the diagnosis and treatment of prostate cancer. He spoke with IO Learning about integrating the recently FDA-approved TULSA...
Dr Busch is the owner of the Busch Center, an imaging center in Alpharetta, Georgia that is dedicated to the diagnosis and treatment of prostate cancer. He spoke with IO Learning about integrating the recently FDA-approved TULSA...
Dr Busch is the owner of the...
04/18/2020
IO Learning